1 / 27

The Art of Medical Prophylaxis, Impacting the Patient Early

Satellite Symposium “Guidelines on Prevention and Treatment of Cancer-Associated Thrombosis” Stockholm , September 16, 2008. The Art of Medical Prophylaxis, Impacting the Patient Early. Anna Falanga, MD Hemostasis and Thrombosis Center Hematology-Oncology Dept

clay
Télécharger la présentation

The Art of Medical Prophylaxis, Impacting the Patient Early

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Satellite Symposium “Guidelines on Prevention and Treatment of Cancer-Associated Thrombosis” Stockholm, September 16, 2008 The Art of Medical Prophylaxis, Impacting the Patient Early Anna Falanga, MD Hemostasis and Thrombosis Center Hematology-Oncology Dept Ospedali Riuniti Bergamo, Italy

  2. Medical Conditions • Although VTE is most often considered to be associated with recent surgery or trauma, 50 to 70% of symptomatic thromboembolic (TE) events and 70 to 80% of fatal pulmonary embolism (PE) occur in non-surgical patients1 • PE accounts for 5-10% of deaths in hospitalized patients, making VTE the most common preventable cause of in-hospital death2 Adapted from: 1. ACCP 2004. 1.Geerts WH, et al. Chest. 2004;126:S338–S400, 2. Cohen A et al. Lancet 2008:371;387-394.

  3. Venous Thromboembolism (VTE) Risk • Hospitalized medical cancer patients are at increased risk for VTE • Out of hospital cancer patients receiving therapy are at risk for VTE

  4. VTE Prevention: We are Failing Our Patients Cancer: 2001 FRONTLINE Survey1— 3891 Respondents 60 52 50 50 43 40 33 Rate of Appropriate Prophylaxis, % 30 29 28 30 20 10 5 0 Surgical Medical US 91 Canada 01 US 02 UK 03 US 07 World 07 Onc Onc Adapted from: 1. Kakkar AK et al. Oncologist. 2003;8:381-88. 2. Anderson FA et al. Ann Intern Med. 1991;115:591-95. 3. Rahim SA et al. Thromb Res. 2003;111:215-19 4. Goldhaber SZ et al. Am J Cardiol. 2004;93:259-62. 5. Rashid J Royal Soc Med 2005. 6. Spencer FA et al. Arch Intern Med 2007;167:1471-75. 7. Tapson VF, et al. Chest 2007;132:936-45.

  5. Recommendations for VTE Prophylaxis in Patients with Cancer Released by International Medical Oncology Societies • AIOM (Italian Medical Oncology Society) - 2006 • ASCO (American Society of Clinical Oncology) - 2007 • NCCN (National Comprehensive Cancer Network) - 2007, 2008 • ESMO (European Society of Medical Oncology) - 2008

  6. Recommendations for VTE Prophylaxis in Hospitalized Patients with Cancer • Hospitalized patients with cancer should be considered candidates for VTE prophylaxis in the absence of bleeding or other contraindications to anticoagulation

  7. Contraindications to Anticoagulation • Active, uncontrollable bleeding • Active cerebrovascular hemorrhage • Dissecting or cerebral aneurysm • Bacterial endocarditis • Pericarditis, active peptic or other GI ulceration • Severe, uncontrolled or malignant hypertension • Severe head trauma • Pregnancy (warfarin) • Heparin-induced thrombocytopenia (heparin, LMWH) • Epidural catheter placement.

  8. Prophylaxis in Acutely Ill Medical Patients • No randomized clinical trials designed a priori for hospitalized medical cancer patients • Randomized, placebo-controlled trials in acutely ill hospitalized medical patients • MEDENOX1- enoxaparin 40 mg daily • PREVENT2 - dalteparin 5000U daily • ARTEMIS3 - fondaparinux 2.5 mg daily Adapted from: 1. Samama et al. N Engl J Med 1999;341:793-800; 2. Leizorovicz et al. Circulation 2004;110:874-79; 3. Cohen et al. Blood 2003; 102(11): 15.

  9. Thromboprophylaxis of Medical Patients: Clear Benefits Over Placebo RRR 63% 45% 47% Study RRR NNT Prophylaxis Patients with VTE, % MEDENOX1 63% 10 Placebo Enoxaparin 40 mg PREVENT2 49% 45 Placebo Dalteparin ARTEMIS3 47% 20 Placebo Fondaparinux 14.9* (n=288) P<0.001 5.5 (n=291) 5.0 (n=1,473)† P=0.0015 2.8 (n=1,518) 10.5‡(n=323) 5.6 (n=321) P=0.029 *VTE at day 14; †VTE at day 21; ‡VTE at day 15. NNT = number needed to treat; RRR = relative risk reduction. Adapted from: 1Samama et al. N Engl J Med 1999;341:793-800.2Leizorovicz et al. Circulation 2004;110:874-9. 3Cohen et al. Br Med J 2006.

  10. Proximal DVT + Symptomatic VTE at D14-21 MEDENOX PREVENT ARTEMIS Dalte. 2.6 % Fond. 1.5 % Enox. 2.1 % Placebo 5.0 % Placebo 3.4 % Placebo 6.6 % P = 0.002 P = 0.037 P = 0.085

  11. EXCLAIM: Study Design Enoxaparin 40 mg s.c. q.d. Enoxaparin 40 mg s.c. q.d. R Placebo 6-month follow-up 38±4 Systematic Duplex ultrasound Days 10±4 • Prospective, randomized, double-blind • 5,090 patients: enrollment completed

  12. Age > 75 years OR • History of VTE OR • Diagnosis of cancer + Inclusion Criteria Initial inclusion criteria • Age  40 years • Recent immobilization ( 3 days) • Acute medical illness • Heart failure, NYHA class III/IV • Acute respiratory insufficiency • Other acute medical conditions including: • post-acute ischemic stroke • acute infection without septic shock • active cancer Amended inclusion criteria Level 1 mobility (total bed rest or sedentary patients) Level 2 mobility (Level 1 withbathroom privileges) or Adapted from Hull et al. J Thromb Thrombolysis. 2006; 22:31-38.

  13. Placebo (N=1681 efficacy pop; N=2027 safety pop) Enoxaparin (N=1666 efficacy pop; N=2013 safety pop) NNT 224 121 46 NNH NNT Summary of Efficacy and Safety:End of the Double-blind Period P=0.0011 6 5 P=0.019 P=0.0109 4 Incidence (%) 3 2 1 0 VTE events Symptomatic DVT Major bleeding NNT = number needed to treat NNH = number needed to harm

  14. Recommended Dose: Venous Thromboembolism Prophylaxis

  15. Prophylaxis in Medical Patients: Ambulatory Cancer Patients • The role of thromboprophylaxis in ambulatory cancer patients during chemotherapy and hormone therapy is not established. • One double-blind placebo-controlled RCT demonstrated the efficacy of low-intensity warfarin (INR 1.3-1.9) in patients receiving chemotherapy for metastatic breast cancer (Levine MN et al, Lancet 1994).

  16. Double Blind Randomized Trial of Very-low-dose Warfarin (INR 1.3-1.9) for Prevention of Thromboembolism in Stage IV Breast Cancer Patients * Warfarin Placebo p= n=152 n=159 Thromboembolic events 1 7 0.031 relative risk reduction = 85% * women receiving chemotherapy for metastatic breast cancer Adapted from Levine et al., Lancet 1994.

  17. Warfarin Prophylaxis: Limitations • Very difficult schedule • Interaction with cytotoxics • Tested only in breast cancer

  18. Prophylaxis of VTE in Medical Cancer Patients • LMWH benefits • Predictable anticoagulant effect • Single daily administration • Reduced toxicity (thrombocytopenia, osteoporosis) • Acceptable safety profile in oncological patient (long term use in recent studies: FAMOUS, CLOT)

  19. Primary Prophylaxis During Chemotherapy: LMWH Recent Closed Studies Adapted from: 1 Haas J TrombHaemost2005, suppl. 1, Abs OR059; 2 Perry et al. Thromb Res 2007, suppl. 2, Abs PO40.

  20. Primary Prophylaxis During Chemotherapy:LMWH Ongoing Studies Adapted from ASCO 2007.

  21. Recommendations for Primary VTE Prophylaxis in Ambulatory Patients with Cancer • Current guidelines do not recommend: • Routine prophylaxis with an antithrombotic agent in ambulatory cancer patients

  22. Special consideration: Prophylaxis in Multiple Myeloma patients • Prophylaxis with LMWH or adjusted dose warfarin (INR~1.5) is recommended in multiple myeloma patients receiving thalidomide or lenalidomide + chemotherapy or dexamethasone (high VTE risk). • However: • No RCTs available • Recommendation is based on extrapolation from non-randomized trials or randomized studies in other similar high-risk categories • Well-designed RCTs are urgently needed Adapted from ASCO Guidelines, JCO 2007.

  23. Central Venous Catheter (CVC) – Related Thrombosis

  24. Prophylaxis of CVC - Related Thrombosis • The presence of CVC is a risk factor for VTE. • Three recent clinical trials have assessed that the incidence of CVC-related symptomatic thrombosis is approximately 3% to 4%. • These trials failed to show a significant effect of prophylaxis with 1 mg fixed dose warfarin, or LMWH dalteparin, or LMWH enoxaparin in reducing symptomatic and asymptomatic thrombosis in patients with cancer.

  25. Randomised Controlled Clinical Trials of Prophylaxis of CVC - Related Thrombosis * Symptomatic events °Routine venography at 6 weeks

  26. Recommendations for Prophylaxis for CVC – Related Thrombosis • Current guidelines agree that extensive, routine prophylaxis to prevent CVC-related VTE is not recommended. To date prophylaxis might be tailored according to individual risk level.

  27. Conclusion • Evidence from epidemiological and clinical studies demonstrates that not only surgical patients but also medical patients with acute medical conditions and predisposing risk factors are at significant risk of VTE. • Hospitalized cancer patients should be assessed for risk of VTE and given appropriate thromboprophylaxis. • Early intervention with thromboprophylaxis (i.e. LMWH) will impact cancer patient outcome.

More Related